[go: up one dir, main page]

MX9606041A - Forma de dosificacion de rapida disolucion. - Google Patents

Forma de dosificacion de rapida disolucion.

Info

Publication number
MX9606041A
MX9606041A MX9606041A MX9606041A MX9606041A MX 9606041 A MX9606041 A MX 9606041A MX 9606041 A MX9606041 A MX 9606041A MX 9606041 A MX9606041 A MX 9606041A MX 9606041 A MX9606041 A MX 9606041A
Authority
MX
Mexico
Prior art keywords
fast dissolving
dosage forms
dissolving dosage
fast
nonrupturable
Prior art date
Application number
MX9606041A
Other languages
English (en)
Other versions
MXPA96006041A (es
Inventor
Michelle Elizabeth Brideau
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Priority claimed from PCT/US1995/006855 external-priority patent/WO1995033446A1/en
Publication of MXPA96006041A publication Critical patent/MXPA96006041A/es
Publication of MX9606041A publication Critical patent/MX9606041A/es

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

Una composicion de enmascaramiento de sabor de rápida disolucion, irrompible que provee liberacion inmediata de ingredientes activos farmacéuticamente aceptables.
MX9606041A 1995-05-31 1995-05-31 Forma de dosificacion de rapida disolucion. MX9606041A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US253890 1994-06-03
PCT/US1995/006855 WO1995033446A1 (en) 1994-06-03 1995-05-31 Fast dissolving dosage forms

Publications (2)

Publication Number Publication Date
MXPA96006041A MXPA96006041A (es) 1998-02-01
MX9606041A true MX9606041A (es) 1998-02-28

Family

ID=39165200

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9606041A MX9606041A (es) 1995-05-31 1995-05-31 Forma de dosificacion de rapida disolucion.

Country Status (1)

Country Link
MX (1) MX9606041A (es)

Similar Documents

Publication Publication Date Title
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
GB9700878D0 (en) Dosage forms and method for ameliorating male erectile dysfunction
TWI235068B (en) Sustained-release pharmaceutical composition
CA2259148A1 (en) Solid oral dosage forms of valsartan
HU9700589D0 (en) Extended release formulation
AU1227899A (en) Osmotic medicament releasing system
IL141762A0 (en) New oral formulations
MY129356A (en) Electrospun pharmaceutical compositions
MY114889A (en) 1-phenyl-3-dimethylamino-propane derivatives having pharmacological activity
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
CA2427815A1 (en) Controlled release hydrocodone formulations
PT893992E (pt) Formas de dosagem oral de desintegracao rapida
AU5651696A (en) Substituted 1-phenyl-3-pyrazolecarboxamides active on nurotensin receptors, their preparation and pharmaceutical compositions containing them
NZ298769A (en) use of progesterone-antagonistic and anti-estrogen compounds in a single dose for female contraception
CA2294783A1 (fr) Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine
CA2622805A1 (en) Compressed tablets comprising valsartan
NZ504460A (en) Sustained release formulations containing venlafaxine
CA2325739A1 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
IL150528A0 (en) Ibuprofen containing active agent preparation
HRP20010684B1 (en) Directly compressible matrix for controlled release of single daily doses of clarithromycin
MX9603606A (es) N-metil-n-[(1s)-1-fenil-2-((3s)-3-hidroxipirrolidin-1-il) etil]-2,2-difenil-acetamida.
WO2002015933A3 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
ZA966047B (en) Therapeutic agents.
BG106342A (en) Low-dose tablets and preparation method